Executive Compensation - Biotechnology | Company | Executive | Title | Total Cash | Total Compensation | | MedImmune Inc. | David M. Mott | President, CEO and Vice Chairman | $1,491,667.00 | $15,330,501.00 | | MedImmune Inc. | Melvin D. Booth | President and COO | $908,334.00 | $5,521,279.00 | | MedImmune Inc. | James F. Young, Ph.D. | President/Research and Development | $845,833.00 | $5,458,778.00 | | Human Genome Sciences Inc. | William A. Haseltine, Ph.D. | CEO | $700,850.00 | $3,428,487.00 | | MedImmune Inc. | Armando Anido, R.Ph. | Senior Vice President | $471,667.00 | $3,423,952.00 | | Novavax Inc. | Nelson M. Sims | President and CEO | $157,692.00 | $3,344,303.00 | | MedImmune Inc. | Wayne T. Hockmeyer, Ph.D. | Chairman | $950,000.00 | $3,256,472.00 | | Advancis Pharmaceutical Corp. | Edward M. Rudnic | President and CEO | $465,000.00 | $3,256,163.00 |
|
© 2004 The Washington Post Company |
 |
